Back to Search Start Over

FDA Green-Lights Tirzepatide, Marketed as Zepbound, for Chronic Weight Management.

Authors :
Abbasi J
Source :
JAMA [JAMA] 2023 Dec 12; Vol. 330 (22), pp. 2143-2144.
Publication Year :
2023

Subjects

Subjects :
Humans
Disease Management
United States Food and Drug Administration legislation & jurisprudence
Chronic Disease
Anti-Obesity Agents therapeutic use
Obesity drug therapy

Details

Language :
English
ISSN :
1538-3598
Volume :
330
Issue :
22
Database :
MEDLINE
Journal :
JAMA
Publication Type :
Academic Journal
Accession number :
37966831
Full Text :
https://doi.org/10.1001/jama.2023.24539
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details